VISCHER advises Inthera Bioscience AG, a Zurich based biopharmaceutical company, developing first-in-class targeted small molecule therapies for solid tumors.

The CHF 10.5 m (EUR 9.6 m) series A financing round was led by Merck Ventures, with equal contribution from Aglaia BioMedical Ventures and Novo Seeds and the participation of a private investor.

In conjunction with the financing round, Emmanuelle Coutanceau of Novo Seeds and Keno Gutierrez of Merck Ventures have joined the company’s Board of Directors. Earlier this year, the Board of Directors had already been strengthened with two experienced biotech executives, Klaus Schollmeier, who has assumed the Chairman role, and Anker Lundemose, joining as independent member.
Inthera Bioscience employs a proprietary technology platform to rationally design small molecule inhibitors of intracellular protein-protein interactions (PPIs). The company’s drug discovery programs are focused on the development of novel first-in-class oral agents blocking aberrant cell signaling in solid tumors, which are currently in pre-clinical development.

The VISCHER team includes Christian Wyss (Partner), Dania Salvisberg-Schneider (Senior Associate), both Corporate and Nadia Tarolli (Partner), Tax.